Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms

被引:9
作者
Belancic, Andrej [1 ,2 ]
Klobucar, Sanja [3 ,4 ]
机构
[1] Clin Hosp Ctr Rijeka, Dept Clin Pharmacol, Rijeka 51000, Croatia
[2] Univ Rijeka, Fac Med, Dept Basic & Clin Pharmacol Toxicol, Rijeka 51000, Croatia
[3] Clin Hosp Ctr Rijeka, Dept Internal Med, Div Endocrinol Diabet & Metab Dis, Rijeka 51000, Croatia
[4] Univ Rijeka, Fac Med, Dept Internal Med, Rijeka 51000, Croatia
来源
DIABETOLOGY | 2023年 / 4卷 / 03期
关键词
antidiabetic; antihyperglycemic; cardioprotection; cardiovascular outcome trial; clinical trials; diabetes; pharmacology; renal outcomes; renoprotection; sodium-glucose co-transporter 2 inhibitors; SGLT2; INHIBITORS;
D O I
10.3390/diabetology4030022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been linked to beneficial effects on cardiovascular risk factors, blood pressure, body weight, and lipid profile, according to a substantial body of literature. Significant cardiac and renal benefits with the use of SGLT2 inhibitors have been shown in patients with type 2 diabetes, as well as in those with heart failure and/or chronic kidney disease (CKD), regardless of diabetes status, in subsequent large cardiovascular outcome trials. Thus, SGLT2 inhibitors have become a mainstay of therapy for type 2 diabetes in patients with established cardiovascular disease and CKD due to their benefits for the heart and kidneys. Based on data from randomized controlled trials and meta-analyses, this article attempts to present a thorough review of the mechanism of action, as well as the benefits of SGLT2 inhibitors for cardiac and renal protection. On the basis of a growing body of literature on diabetes and other conditions, clinical practice guidelines have been updated to suggest the use of SGLT2 inhibitors in specific patient populations. These modifications will also be concisely described, based on evidence-based medicine principles.
引用
收藏
页码:251 / 258
页数:8
相关论文
共 38 条
[1]   National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020 [J].
Adhikari, Rishav ;
Jha, Kunal ;
Dardari, Zeina ;
Heyward, James ;
Blumenthal, Roger S. ;
Eckel, Robert H. ;
Alexander, G. Caleb ;
Blaha, Michael J. .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (09)
[2]   Empagliflozin in Heart Failure with a Preserved Ejection Fraction [J].
Anker, Stefan D. ;
Butler, Javed ;
Filippatos, Gerasimos ;
Ferreira, Joao P. ;
Bocchi, Edimar ;
Boehm, Michael ;
Brunner-La Rocca, Hans-Peter ;
Choi, Dong-Ju ;
Chopra, Vijay ;
Chuquiure-Valenzuela, Eduardo ;
Giannetti, Nadia ;
Gomez-Mesa, Juan Esteban ;
Janssens, Stefan ;
Januzzi, James L. ;
Gonzalez-Juanatey, Jose R. ;
Merkely, Bela ;
Nicholls, Stephen J. ;
Perrone, Sergio V. ;
Pina, Ileana L. ;
Ponikowski, Piotr ;
Senni, Michele ;
Sim, David ;
Spinar, Jindrich ;
Squire, Iain ;
Taddei, Stefano ;
Tsutsui, Hiroyuki ;
Verma, Subodh ;
Vinereanu, Dragos ;
Zhang, Jian ;
Carson, Peter ;
Lam, Carolyn Su Ping ;
Marx, Nikolaus ;
Zeller, Cordula ;
Sattar, Naveed ;
Jamal, Waheed ;
Schnaidt, Sven ;
Schnee, Janet M. ;
Brueckmann, Martina ;
Pocock, Stuart J. ;
Zannad, Faiez ;
Packer, Milton .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1451-1461
[3]   SGLT2 inhibitors in older adults: overcoming the age barrier [J].
Bellary, Srikanth ;
Barnett, Anthony H. .
LANCET HEALTHY LONGEVITY, 2023, 4 (04) :E127-E128
[4]   Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials [J].
Berhan, Asres ;
Barker, Alex .
BMC ENDOCRINE DISORDERS, 2013, 13
[5]   Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes [J].
Cannon, Christopher P. ;
Pratley, Richard ;
Dagogo-Jack, Samuel ;
Mancuso, James ;
Huyck, Susan ;
Masiukiewicz, Urszula ;
Charbonnel, Bernard ;
Frederich, Robert ;
Gallo, Silvina ;
Cosentino, Francesco ;
Shih, Weichung J. ;
Gantz, Ira ;
Terra, Steven G. ;
Cherney, David Z. I. ;
McGuire, Darren K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15) :1425-1435
[6]   Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes [J].
Clar, Christine ;
Gill, James Alexander ;
Court, Rachel ;
Waugh, Norman .
BMJ OPEN, 2012, 2 (05)
[7]   Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis [J].
Donnan, Jennifer R. ;
Grandy, Catherine A. ;
Chibrikov, Eugene ;
Marra, Carlo A. ;
Aubrey-Bassler, Kris ;
Johnston, Karissa ;
Swab, Michelle ;
Hache, Jenna ;
Curnew, Daniel ;
Hai Nguyen ;
Gamble, John-Michael .
BMJ OPEN, 2019, 9 (01)
[8]  
European Medicines agency, About us
[9]   Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors [J].
Fadini, Gian Paolo ;
Del Prato, Stefano ;
Avogaro, Angelo ;
Solini, Anna .
DIABETES OBESITY & METABOLISM, 2022, 24 (02) :177-186
[10]   New Antidiabetes Medications and Their Cardiovascular and Renal Benefits [J].
Ferro, Enrico G. ;
Elshazly, Mohamed B. ;
Bhatt, Deepak L. .
CARDIOLOGY CLINICS, 2021, 39 (03) :335-351